Beximco claims to be the first to produce Remdesivir, not Eskayef | The Business Standard
Skip to main content
  • Epaper
  • Economy
    • Aviation
    • Banking
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • Subscribe
    • Epaper
    • GOVT. Ad
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
The Business Standard

Monday
May 12, 2025

Sign In
Subscribe
  • Epaper
  • Economy
    • Aviation
    • Banking
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • Subscribe
    • Epaper
    • GOVT. Ad
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
MONDAY, MAY 12, 2025
Beximco claims to be the first to produce Remdesivir, not Eskayef

Pharma

TBS Report
09 May, 2020, 07:40 pm
Last modified: 09 May, 2020, 10:22 pm

Related News

  • While in power, Salman's Amar Bond shone bright. Out of power, 2nd bond flopped
  • Beximco counters ACC allegation of Covid-19 vaccine scam
  • With maturity looming, Beximco's sukuk repayment uncertain as incomes dry up
  • SC clears way for independent directors to take role in 3 Beximco firms
  • The school where masons and road workers learn their trade

Beximco claims to be the first to produce Remdesivir, not Eskayef

TBS Report
09 May, 2020, 07:40 pm
Last modified: 09 May, 2020, 10:22 pm
File Photo: Vials of investigational coronavirus disease (Covid-19) treatment drug remdesivir are capped at a Gilead Sciences facility in La Verne, California, US March 18, 2020. Picture taken March 18, 2020. Gilead Sciences Inc/Handout via Reuters
File Photo: Vials of investigational coronavirus disease (Covid-19) treatment drug remdesivir are capped at a Gilead Sciences facility in La Verne, California, US March 18, 2020. Picture taken March 18, 2020. Gilead Sciences Inc/Handout via Reuters

Beximco Pharmaceuticals Ltd claims that it is the first company in Bangladesh, not Eksayef, to produce the potential coronavirus drug Remdesivir.

The pharmaceutical company made the claim in a press note issued on Saturday.

Here is the full press note from Beximco.

The Business Standard Google News Keep updated, follow The Business Standard's Google news channel

"Beximco Pharmaceuticals Ltd has taken notice of the news published in the online version of Daily Star and Daily Prothom Alo on May 8, 2020, (subsequently in their print versions the next day)  titled "Eskayef first to produce Remdesivir in the country" and "করোনার চিকিৎসায় দেশে প্রথম রেমডেসিভির উৎপাদন করল এসকেএফ", wherein it is mentioned that the company initiated distributing preparations from Friday. This was also republished by other news outlets.

We believe the story items were factually incorrect.

We would like to clarify that Beximco Pharma not only was the first company in Bangladesh to produce this drug, but also the only company which has submitted final product samples to the drug regulatory authority, Directorate General of Drug Administration (DGDA), for testing and approval. After producing this generic drug and successfully conducting all necessary tests in house we submitted final product samples to DGDA on 7th May 2020, for testing and approval.

This is a mandatory legal requirement which must be complied with before any company can distribute any drug in Bangladesh or globally. Beximco Pharma refrained from announcing that it has produced the drug because it felt doing so without being validated by the regulatory body would have been irresponsible and unethical and would have misled the public.

We are releasing this press note in greater public interest to clarify the matter and dispel any confusion that may have been caused by the above-mentioned news items."

Corporates / Top News / Covid-19 in Bangladesh

Beximco / Eskayef / COVID-19 / Coronavirus / remdesivir

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • EC Secretary Akhtar Ahmed holds a press briefing at the EC office in Agargaon, Dhaka on 12 May 2025. Photo: TBS
    EC scraps banned AL's registration, disqualifies for JS elections
  • Illustration: TBS
    Awami League, all its affiliates now officially banned
  • Why is India 'pushing in' on Bangladesh?
    Why is India 'pushing in' on Bangladesh?

MOST VIEWED

  • Chief Adviser Muhammad Yunus holds a high-level meeting on the country's capital market at the State Guest House Jamuna in Dhaka on 11 May 2025. Photo: PID
    Chief adviser orders listing of SOEs, govt-linked MNCs to revitalise stock market
  • Bangladesh Bank. File Photo: Collected
    Govt can now temporarily take over any bank, NBFI
  • Governments often rely on foreign loans. Russia’s loans covered 90% of the Rooppur Nuclear Power plant project's cost. Photo: Collected
    18 engineers of Rooppur Nuclear Power Plant dismissed following week-long unrest
  • Food, fertilisers, raw materials: NBR plans advance tax on 200 duty-free imports
    Food, fertilisers, raw materials: NBR plans advance tax on 200 duty-free imports
  • Solar power project in Chattogram. Photo: TBS
    Govt's 5,238MW grid-tied solar push faces tepid response from investors
  • Photo shows the high-level meeting with the LDC Graduation Committee held at the State Guest House Jamuna on Sunday, 11 May 2025. Photo: CA Press Wing
    CA Yunus urges swift, coordinated action for LDC graduation

Related News

  • While in power, Salman's Amar Bond shone bright. Out of power, 2nd bond flopped
  • Beximco counters ACC allegation of Covid-19 vaccine scam
  • With maturity looming, Beximco's sukuk repayment uncertain as incomes dry up
  • SC clears way for independent directors to take role in 3 Beximco firms
  • The school where masons and road workers learn their trade

Features

Stryker was released three months ago, with an exclusive deal with Foodpanda. Photo: Courtesy

Steve Long’s journey from German YouTuber to Bangladeshi entrepreneur

1h | Panorama
Photo: Courtesy

No drill, no fuss: Srijani’s Smart Fit Lampshades for any space

1d | Brands
Photo: Collected

Bathroom glow-up: 5 easy ways to upgrade your washroom aesthetic

1d | Brands
The design language of the fourth generation Velfire is more mature than the rather angular, maximalist approach of the last generation. PHOTO: Arfin Kazi

2025 Toyota Vellfire: The Japanese land yacht

1d | Wheels

More Videos from TBS

US-China 90-day deal changes stock markets

US-China 90-day deal changes stock markets

5m | TBS World
Did India and Pakistan really go to war?

Did India and Pakistan really go to war?

20m | Others
Shaun Tait named fast bowling coach of the Bangladesh National Team

Shaun Tait named fast bowling coach of the Bangladesh National Team

40m | TBS SPORTS
Why is India 'pushing in' on Bangladesh?

Why is India 'pushing in' on Bangladesh?

1h | Podcast
EMAIL US
contact@tbsnews.net
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Advertisement
  • Privacy Policy
  • Comment Policy
Copyright © 2025
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net